Emixustat (黃斑部水腫·黃斑部病變) :預測·市場分析
Emixustat (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 111 Pages
|Emixustat (黃斑部水腫·黃斑部病變) :預測·市場分析 Emixustat (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023|
|出版日期: 2014年10月31日||內容資訊: 英文 111 Pages||
Emixustat hydrochloride(ACU-4429)是Acucela公司所開發，活用治療伴隨地圖狀萎縮GA的乾燥型老年性黃斑部病變 (dAMD) 用視覺循環調製技術 (VCM) 的口服藥。
Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.
Emixustat hydrochloride (formerly known as ACU-4429) is an orally-dosed VCM that is designed to be selective for rod photoreceptors and is being developed for the treatment of GA associated with dAMD. This was the first internally-developed compound by Acucela, a Seattle-based biotechnology company. Acucela has one issued US patent (No. 7,982,071) and seven pending US patents for emixustat, all of which will expire in or around 2029.